CEVR analyzes the benefits, risks, and costs of strategies to improve health and health care.

About Us

News & Events

Seminar with Brian D Smith, BSc, DipM PhD FRSA

New Drugs, Fair Prices: Managing the Pharmaceutical Innovation Ecosystem for Sustainable, Affordable New Medicines In this presentation and discussion...

Read more December 1, 2022
Health Policy Seminar with Hadley Stevens Smith, PhD, MPSA

The value flower meets the double helix: Measuring value of pediatric genomic medicine Over the last decade, genomic sequencing technologies have d...

Read more November 16, 2022
Virtual Health Policy Seminar with Nancy Keating, MD, MPH

Alternative Payments in Oncology: Past, Present, Future (?) Nancy L. Keating, MD, MPH, is Professor of Health Care Policy and Medicine at Harvard Med...

Read more October 12, 2022
View All News & Events

Recent Publications

Journal of Managed Care & Specialty Pharmacy
When are breakthrough therapies cost-effective?
View publication
July 28, 2022
JAMA Network Open
Racial and ethnic differences in hospice use and hospitalizations at end-of-life among Medicare beneficiaries with dementia
View publication
June 9, 2022
Medical Decision Making
Trends in author-reported cost-effectiveness thresholds in the United States from 1995 to 2018: Implications for discount rates
View publication
May 7, 2022
The American Journal of Managed Care
Patients’ access to 2018 FDA-approved drugs 1 year post approval
View publication
April 12, 2022
PharmacoEconomics
Addressing challenges to alternative payment models for new Alzheimer’s disease therapies for US commercial payers
View publication
May 13, 2022
Genetics in Medicine
Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions
View publication
April 8, 2022
Value in Health
A systematic review of economic evaluations of COVID-19 interventions: Considerations of non-health impacts and distributional issues
View publication
April 6, 2022
Value in health
The impact of broader value elements on cost-effectiveness analysis: Two case studies
View publication
March 18, 2022
Value in Health
The history and future of the “ISPOR value flower”: Addressing limitations of conventional cost-effectiveness analysis
View publication
March 9, 2022
Orphanet Journal of Rare Diseases
Patients' access to rare neuromuscular disease therapies varies across US private insurers
View publication
February 5, 2022
Health Affairs Forefront
The certainty of uncertainty in health technology assessment
View publication
January 26, 2022
Health Affairs Forefront
Medicare’s Aducanumab decision highlights needed reforms to FDA and CMS regulatory pathways
View publication
January 25, 2022
Applied Health Economics and Health Policy
Herd immunity effects in cost‑effectiveness analyses among low‑ and middle‑income countries
View publication
January 10, 2022
Journal of Developmental and Behavioral Pediatrics
Developmental behavioral pediatrician perspectives on decision-making in early treatment planning for children with autism spectrum disorder
View publication
October 12, 2021
View All Publications

The CEVR Team

Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.

Meet the CEVR Team

Our Databases

Our comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.

CEA Registry

The CEA Registry is a comprehensive database of 9,080 cost-utility analyses on a wide variety of diseases and treatments.

View Registry

Global Health CEA Registry

The GH CEA Registry is the first comprehensive database to compile articles utilizing the “cost-per-DALY averted” metric to measure the efficacy of health interventions.

View Registry

SPEC Database

The Specialty Drug Evidence and Coverage (SPEC) Database is a new data resource developed with the goal of providing an empirical basis to commercial payer specialty drug coverage.

View Database
Learn About Our Databases